Intervention Review

Rofecoxib for osteoarthritis

  1. Sarah E Garner1,*,
  2. Dogan Fidan2,
  3. Ruth R Frankish1,
  4. Lara Maxwell3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 24 JAN 2005

Assessed as up-to-date: 16 NOV 2004

DOI: 10.1002/14651858.CD005115

How to Cite

Garner SE, Fidan D, Frankish RR, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD005115. DOI: 10.1002/14651858.CD005115.

Author Information

  1. 1

    National Institute for Clinical Excellence, Appraisals Team, London, UK

  2. 2

    Aventis Pharma Ltd., Health Economics Unit, London, UK

  3. 3

    University of Ottawa, Institute of Population Health, Ottawa, Ontario, Canada

*Sarah E Garner, Appraisals Team, National Institute for Clinical Excellence, MidCity Place, 71 High Holborn, London, WC1V 6NA, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JAN 2005


Cited in:


This article has been cited by:

  1. You have free access to this content1
    Bruno Georg Oertel, Jörn Lötsch, Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research, British Journal of Pharmacology, 2013, 168, 3
  2. 2
    George Liberopoulos, Nikolaos A. Trikalinos, John P.A. Ioannidis, The elderly were under-represented in osteoarthritis clinical trials, Journal of Clinical Epidemiology, 2009, 62, 11, 1218


  3. 3
    Matthew J Leach, Saravana Kumar, The clinical effectiveness of Ginger (Zingiber officinale) in adults with osteoarthritis, International Journal of Evidence-Based Healthcare, 2008, 6, 3